News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (308 of 354). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 354). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (35 of 354). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 266 of 354 items have one.
U.S. POINTER Study Shows Structured Lifestyle Program Improves Cognition in Older Adults at Risk
The two-year U.S. POINTER trial of 2,111 older adults at five U.S. sites found that both a structured and a self-guided multidomain lifestyle intervention (diet, exercise, cognitive/social engagement, health monitoring) improved cognition, with the structured program producing significantly greater gains. Results were published simultaneously in JAMA.
Why it matters: First large U.S. randomized trial showing an accessible lifestyle program can protect cognition in a diverse at-risk population, offering a non-drug strategy alongside emerging medications.
Read at Alzheimer's Association / AAIC → Archived copy (6 Sep 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.